MedPath
FDA Approval

Sodium Sulfacetamide 10 % and Sulfur 2 % Cleanser

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
SOHM, Inc
DUNS: 009303848
Effective Date
May 3, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Sulfacetamide(100 mg in 1 g)
Sulfur(20 mg in 1 g)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

SOHM, Inc

009303848

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Sodium Sulfacetamide 10 % and Sulfur 2 % Cleanser

Product Details

NDC Product Code
50405-851
Route of Administration
TOPICAL
Effective Date
May 3, 2023
Code: 4NRT660KJQClass: ACTIBQuantity: 100 mg in 1 g
SulfurActive
Code: 70FD1KFU70Class: ACTIBQuantity: 20 mg in 1 g
ALOE VERA LEAFInactive
Code: ZY81Z83H0XClass: IACT
CAMELLIA OLEIFERA LEAFInactive
Code: 5077EL0C60Class: IACT
BUTYLATED HYDROXYTOLUENEInactive
Code: 1P9D0Z171KClass: IACT
CETYL ALCOHOLInactive
Code: 936JST6JCNClass: IACT
DISODIUM OLEAMIDO MEA-SULFOSUCCINATEInactive
Code: 5M1101WGSYClass: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86KClass: IACT
MAGNESIUM ALUMINUM SILICATEInactive
Code: 6M3P64V0NCClass: IACT
METHYLPARABENInactive
Code: A2I8C7HI9TClass: IACT
GLYCERINInactive
Code: PDC6A3C0OXClass: IACT
PEG-100 STEARATEInactive
Code: YD01N1999RClass: IACT
GLYCERYL MONOSTEARATEInactive
Code: 230OU9XXE4Class: IACT
SODIUM COCOYL ISETHIONATEInactive
Code: 518XTE8493Class: IACT
PROPYLPARABENInactive
Code: Z8IX2SC1OHClass: IACT
SODIUM METHYL COCOYL TAURATEInactive
Code: JVL98CG53GClass: IACT
STEARYL ALCOHOLInactive
Code: 2KR89I4H1YClass: IACT
SODIUM THIOSULFATEInactive
Code: HX1032V43MClass: IACT
XANTHAN GUMInactive
Code: TTV12P4NEEClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT

Drug Labeling Information

Complete FDA-approved labeling information including indications, dosage, warnings, contraindications, and other essential prescribing details.

PRECAUTIONS SECTION

PRECAUTIONS:

**General -**If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but Sulfacetamide Sodium and Sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for patients - Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis and Impairment of Fertility - Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy: Category C - Animal reproduction studies have not been conducted with Sulfacetamide Sodium and Sulfur lotion. It is also not known whether Sulfacetamide Sodium and Sulfur cleanser can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sulfacetamide Sodium and Sulfur cleanser should be given to a pregnant woman only if clearly needed.


HOW SUPPLIED SECTION

HOW SUPPLIED:

Sulfacetamide Sodium 10% and Sulfur 2% cleanser is supplied in
8 oz (227 g) bottle NDC #50405-851-01

Store at 20°-25°C (68°-77°F), excursions permitted between 15°-30°C (59°-86°F). Brief exposure to temperatures up to 40° (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C(77°F); however such exposure should be minimized. Protect from freezing.

Call your doctor about side effects. You may report side effects to FDA at 1-800-FDA-1088.
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN


© Copyright 2025. All Rights Reserved by MedPath